Revvity RVTY Life Sciences — Segment Cost of Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Revvity in its filing.
Tagged under the XBRL concept revv:SegmentCostOfRevenue.
The official record: Revvity’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Revvity's life sciences — segment cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Revvity's life sciences — segment cost of revenue?
- Revvity (RVTY) reported life sciences — segment cost of revenue of $131.57M in Q1 2026.
- How has Revvity's life sciences — segment cost of revenue changed year-over-year?
- Revvity's life sciences — segment cost of revenue increased by 10.3% year-over-year, from $119.32M to $131.57M.
- What is the long-term trend for Revvity's life sciences — segment cost of revenue?
- Over 3 years (2022 to 2025), Revvity's life sciences — segment cost of revenue has grown at a 7.2% compound annual growth rate (CAGR), from $418.83M to $516.3M.
- What does life sciences — segment cost of revenue mean?
- The direct cost to manufacture and deliver Life Sciences products.
- How do you interpret life sciences — segment cost of revenue?
- A rising ratio relative to revenue suggests margin compression due to inflation or supply chain inefficiencies.
- How does life sciences — segment cost of revenue compare across companies?
- Standard 'Cost of Goods Sold' (COGS) metric used across all manufacturing and life science sectors.